Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity
Chaokun Wang, Jiachang Li, Yue Tong, Haotian Chang, Jingyi Xu, Hanchen Zhu, Yongmei Yin, Meng Meng, Rimo Xi · 2025
Read Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity by Chaokun Wang, Jiachang Li, Yue Tong, Haotian Chang, Jingyi Xu, Hanchen Zhu, Yongmei Yin, Meng Meng, Rimo Xi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12719890.txt.
Description
Wang and eight co-authors build a two-headed antibody that hunts a tumor marker with one arm and a T cell homing signal with the other. The goal is to strip HER2-positive tumors of the regulatory T cells that shield them. Blocking that shield body-wide has proven toxic in blood cancers.
Their designs hide the second arm to different degrees, so the drug prefers tumor tissue. The lead candidate, XL-11, killed tumor cells and shield T cells in dishes and shrank tumors in mice with human immune systems. It spared T cells elsewhere better than the older drug it improves on. Memory and drug-level studies rounded out the tests.
Catalog record
| CREATOR | Chaokun Wang, Jiachang Li, Yue Tong, Haotian Chang, Jingyi Xu, Hanchen Zhu, Yongmei Yin, Meng Meng, Rimo Xi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |